Resolving Drug-Drug Interactions: A Guide for Community Pharmacies to Reduce Potential Hospitalizations

Thursday, October 8, 2015

Content Description:
This 2-hour workshop provides participants with a continuing professional development opportunity related to a particular set of evidence-based drug-drug interactions (DDIs) relevant in the care of older patients.

Learning Objectives:
- To appreciate the significance of drug-drug interactions (DDIs) in the elderly population
- To understand current challenges in preventing DDIs
- To identify clinically significant DDIs involving commonly used antibiotics that are not consistently caught on clinical decision support systems (CDSS)
- To review alternative therapeutic options for empiric treatment of uncomplicated urinary tract infections (UTIs), group A streptococcal pharyngitis and community acquired pneumonia (CAP)
- To build confidence in mitigating DDIs with structured documentation forms to communicate drug therapy problems (DTPs) and patient-specific therapeutic recommendations to prescribers

Program Abstract:
Drug-Drug Interactions (DDIs) represent a potential problem for patients that can lead to preventable adverse drug events, including unplanned hospital admission and serious patient harm, up to and including death. As the most accessible healthcare professional, community pharmacists are in a unique position to resolve potential DDIs by monitoring medication therapy and applying evidence-based pharmacotherapy knowledge. Older patients (i.e., age 65 and higher) are at increased risk of DDIs due to progression of chronic diseases, use of multiple medications, and physiological changes. Unfortunately, reliance on pre-programmed point of care clinical decision support systems limits the ability of pharmacists to become aware of recently published evidence-based DDIs. This workshop will provide participants with the tools to identify evidence-based DDIs found to increase the risk of hospitalizations, resolve specific evidence-based DDI pairs, and increase confidence in mitigating DDIs through structured communication with prescribers. A further gain through attendance at this workshop will be an improved awareness of professional cognitive services eligible for provincial reimbursement (e.g. Pharmaceutical Opinion Program in Ontario http://www.health.gov.on.ca/en/pro/programs/drugs/pharmaopinion/).

Acknowledgement:
ISMP Canada would like to acknowledge support from the Canadian Foundation for Pharmacy's Innovation Fund Grant for the implementation of the "Safety Alerts as Drivers for Pharmaceutical Opinion Program" pilot research study (2012-2015).

Audience:
Pharmacists, pharmacy interns, and students

Workshop Level: Intermediate (assumes prior knowledge and understanding of the fundamental concepts behind the different types and mechanisms of drug-drug interactions)

Time: Each workshop session is 2 hours in length; 3 timeslots are available:
- ❒ **Session 1:** 8:30 a.m. – 10:30 a.m.
- ❒ **Session 2:** 11:00 a.m. – 1:00 p.m.
- ❒ **Session 3:** 6:00 p.m. – 8:00 p.m.

Duration: 2 hours

Cost: $150 + HST per participant

Contact Us:
Telephone: 416-733-3131 Ext. 240
Toll Free: 1-866-544-7672 Ext. 240
E-mail: education@ismp-canada.org
Fax: 416-733-1146

Location:
ISMP Canada
Medication Safety Learning Centre
4711 Yonge Street, Suite 501
(Procter & Gamble building)
Toronto, Ontario M2N 6K8

CE Units:
The Canadian Council on Continuing Education in Pharmacy has accredited this program for 2 CEUs.
(CCCEP File # 1260-2014-1242-L-P)

CEP ACCREDITED

Resolving Drug-Drug Interactions: A Guide for Community Pharmacies to Reduce Potential Hospitalizations

Thursday, October 8, 2015

Location:
ISMP Canada
Medication Safety Learning Centre
4711 Yonge Street, Suite 501
(Procter & Gamble building)
Toronto, Ontario M2N 6K8

How to Register:

Fax: 416-733-1146, *Attn: Registration*

Mail: ISMP Canada, *Attn: Registration*
4711 Yonge Street, Suite 501
Toronto, Ontario M2N 6K8

Contact: Registration
Phone: 416-733-3131 Ext. 240
Toll Free: 1-866-544-7672 Ext. 240
Email: registration@ismp-canada.org

REGISTRATION INFORMATION (Please print clearly)

First Name: Last Name:

Company Name:

Mailing Address: Business:

Home:

City: Province: Postal Code:

Telephone: Fax:

Email (to be used for registration confirmation):

Workshop Session

Select a timeslot: ❒ 8:30 a.m. – 10:30 a.m. ❒ 11:00 a.m. – 1:00 p.m. ❒ 6:00 p.m. – 8:00 p.m.

Course Registration Fee

$150 + HST per participant (Enrolment is limited to 8 attendees per session)*

Total payable: $ 169.50

* ISMP Canada reserves the right to cancel or re-schedule the workshop if minimum enrolment is not reached

Method of Payment

Cheques are payable to "ISMP Canada". Registration must be accompanied by payment.

❒ Cheque ❒ VISA® ❒ Mastercard®

Name of Cardholder:

Credit Card #: Expiry Date:

Signature: GST Registration #898242219

The Canadian Council on Continuing Education in Pharmacy has accredited this program for 2 CEUs. (CCCEP File # 1260-2014-1242-L-P)

Cancellation Policy:
Requests for cancellations or refunds must be submitted in writing to ISMP Canada prior to Thursday, October 1, 2015. A $75.00 cancellation fee will apply. Cancellations will not be accepted after October 1, 2015.

Resolving Drug-Drug Interactions: A Guide for Community Pharmacies to Reduce Potential Hospitalizations

Thursday, October 8, 2015

Location: ISMP Canada,
Medication Safety Learning Centre
4711 Yonge Street, Suite 501,
(Procter & Gamble building)
Toronto, Ontario M2N 6K8

AGENDA for ISMP Canada Workshop

TIME:

Each workshop session is 2 hours in length; 3 timeslots are available:

- ❒ **Session 1:** 8:30 a.m. – 10:30 a.m.
- ❒ **Session 2:** 11:00 a.m. – 1:00 p.m.
- ❒ **Session 3:** 6:00 p.m. – 8:00 p.m.

PART 1:

Adverse Drug Reactions (ADRs) and Drug-Drug Interactions (DDIs) in the Elderly Population

PART 2:

Evidence and Management of Clinically Relevant DDIs

PART 3:

Tools to Communicate Drug Therapy Problems (DTPs) and Therapeutic Recommendations to Physicians

PART 4:

Putting It All Together: A Case Example

PART 5:

Testing Your Knowledge

PART 6:

Conclusion